HCG15: A Potential Drug Target and Biomarker (G414761)

Target Name: HCG15

NCBI ID: G414761

HCG15

Other Name(s): HCG16 | HLA complex group 15 | HCG15 variant 2

HCG15: A Potential Drug Target and Biomarker

Human chorionic gonadotropin (HCG) is a hormone produced by the placenta after fertilization occurs. It is a key protein in the development and maintenance of pregnancy, and its levels have been used as a marker for pregnancy and fertility. However, high levels of HCG can also be found in certain diseases and conditions, such as cancer, and this has led to its potential as a drug target or biomarker.

HCG15 is a variant of HCG that has been shown to have potential as a drug target in several studies. It is a single-chain glycoprotein with a molecular weight of approximately 17 kDa. It consists of two major subunits, a monoclonal antibody (mAb) and a human chorionic gonadotropin receptor (hCG receptor) that are fused together. The hCG receptor is a G protein-coupled receptor that is involved in cellular signaling pathways, including pregnancy and fetal development.

One of the reasons why HCG15 has been shown to be a potential drug target is its role in cancer. High levels of HCG15 have been found in various types of cancer, including ovarian, breast, and prostate cancer. These high levels can make them difficult to detect and treat, as traditional cancer treatments may have little effect on HCG15 levels.

Another potential mechanism by which HCG15 may contribute to cancer is its role in cell signaling pathways. Cancer cells often have aberrant signaling pathways, and these pathways can be activated by HCG15. This can lead to the growth and proliferation of cancer cells, making them difficult to control.

In addition to its potential role in cancer, HCG15 has also been shown to be a potential biomarker for several diseases, including infertility and testicular cancer. High levels of HCG15 have been found in the urine and blood of individuals with infertility, which may indicate the presence of undiagnosed fertility disorders. Similarly, high levels of HCG15 have also been found in the urine and blood of individuals with testicular cancer, which may indicate the presence of undiagnosed testicular cancer.

Another potential use for HCG15 is its role in reproductive medicine. HCG15 has been shown to be a potential treatment for infertility by increasing the probability of fertilization. This is because HCG15 has been shown to stimulate the production of follicular eggs by the ovaries, as well as the thickening of the uterine lining, which can improve the chances of fertilization.

HCG15 has also been shown to be a potential biomarker for several other diseases and conditions, including pregnancy and birth defects. High levels of HCG15 have been found in the urine and blood of pregnant women, which may indicate the presence of pregnancy. Similarly, high levels of HCG15 have also been found in the urine and blood of individuals with birth defects, which may indicate the presence of genetic or environmental causes of these conditions.

In conclusion, HCG15 is a variant of HCG that has been shown to have potential as a drug target and biomarker in several studies. Its role in cancer and reproductive medicine makes it an attractive target for future research and development. Further studies are needed to fully understand the potential of HCG15 as a drug and biomarker.

Protein Name: HLA Complex Group 15

The "HCG15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HCG15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets